Using risk factors and markers to predict bacterial respiratory co-/superinfections in COVID-19 patients: is the antibiotic steward’s toolbox full or empty?

References

• Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. DOI:10.1016/S0140-6736(21)02724-0
   PubMed Web of Science ®Google Scholar
• United Nations General Assembly. Declaration of the high-level meeting of the general assembly on antimicrobial resistance. New York: United Nations; 2011. 66th session; 2011–2012 A/RES/66/2.
   Google Scholar
• World Health Organization. Report to the secretary-general of the united nations. No time to wait: securing the future from drug-resistant infections. April 2019.
   Google Scholar
• Spernovasilis NA, Kofteridis DP. COVID-19 and antimicrobial stewardship: what is the interplay? Infect Control Hosp Epidemiol. 2021;42(3):1.
   PubMed Web of Science ®Google Scholar
• Miranda C, Silva V, Capita R, et al. Implications of antibiotics use during the COVID-19 pandemic: present and future. J Antimicrob Chemother. 2020;75(12):3413–3416. DOI:10.1093/jac/dkaa350
   PubMed Web of Science ®Google Scholar
• Rawson TM, Moore LSP, Castro-Sanchez E, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother. 2020;75(7):1681–1684. DOI:10.1093/jac/dkaa194
   PubMed Web of Science ®Google Scholar
• Antimicrobial resistance in the age of COVID-19. Nat Microbiol. 2020;5(6):779. DOI:10.1038/s41564-020-0739-4
   PubMed Web of Science ®Google Scholar
• Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27(4):520–531. DOI:10.1016/j.cmi.2020.12.018
   PubMed Web of Science ®Google Scholar
• Rice TW, Rubinson L, Uyeki TM, et al. Critical illness from 2009 pandemic influenza a virus and bacterial coinfection in the United States. Crit Care Med. 2012 May;40(5):1487–1498. DOI:10.1097/CCM.0b013e3182416f23.
   PubMed Web of Science ®Google Scholar
• Oliva J, Terrier O. Viral and Bacterial Co-Infections in the Lungs: Dangerous Liaisons. Viruses. 2021 Aug 30;13(9):1725. DOI:10.3390/v13091725
   PubMed Web of Science ®Google Scholar
• May M, Chang M, Dietz D, et al. Limited utility of procalcitonin in identifying community-associated bacterial infections in patients presenting with coronavirus disease 2019. Antimicrob Agents Chemother. 2021;65(4): DOI:10.1128/AAC.02167-20
   Web of Science ®Google Scholar
• Vanhomwegen C, Veliziotis I, Malinverni S, et al. Procalcitonin accurately predicts mortality but not bacterial infection in COVID-19 patients admitted to intensive care unit. Ir J Med Sci. 2021;190(4):1649–1652. DOI:10.1007/s11845-020-02485-z
   PubMed Web of Science ®Google Scholar
• Tjendra Y, Al Mana AF, Espejo AP, et al. Predicting COVID-19 severity and outcome in COVID-19 patients: a review of multiple biomarkers. Arch Pathol Lab Med. 2020;144(12):1465–1474. DOI:10.5858/arpa.2020-0471-SA
   PubMed Web of Science ®Google Scholar
• Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622–1629. DOI:10.1016/j.cmi.2020.07.016
   PubMed Web of Science ®Google Scholar
• Karaba SM, Jones G, Helsel T, et al. Prevalence of co-infection at the time of hospital admission in COVID-19 patients, a multicenter study. Open Forum Infect Dis. 2021;8(1): DOI:10.1093/ofid/ofaa578
   Web of Science ®Google Scholar
• Coenen S, de la Court JR, Buis DTP, et al. Low frequency of community-acquired bacterial co-infection in patients hospitalized for COVID-19 based on clinical, radiological and microbiological criteria: a retrospective cohort study. Antimicrob Resist Infect Control. 2021;10(1):1–10. DOI:10.1186/s13756-021-01024-4
   PubMed Web of Science ®Google Scholar
• World Health Organization. Living guidance for clinical management of COVID-19. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2.
   Google Scholar
• Sieswerda E, de Boer MGJ, Bonten MMJ, et al. Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline. Clin Microbiol Infect. 2021;27(1):61–66. DOI:10.1016/j.cmi.2020.09.041
   PubMed Web of Science ®Google Scholar
• Baethge C, Goldbeck-Wood S, Mertens S. Sanra—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4(1). DOI:10.1186/s41073-019-0064-8
   PubMedGoogle Scholar
• Sager R, Kutz A, Mueller B, et al. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med. 2017;15(1). DOI:10.1186/s12916-017-0795-7
   PubMedGoogle Scholar
• Schuetz P, Maurer P, Punjabi V, et al. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. crit care. 2013;17(3):R115. DOI:10.1186/cc12787
   PubMed Web of Science ®Google Scholar
• Schuetz P, Birkhahn R, Sherwin R, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin monitoring Sepsis (MOSES) study. Crit Care Med. 2017 May;45(5):781–789. DOI:10.1097/CCM.0000000000002321.
   PubMed Web of Science ®Google Scholar
• Dolci A, Robbiano C, Aloisio E, et al. Searching for a role of procalcitonin determination in COVID-19: a study on a selected cohort of hospitalized patients. Clin Chem Lab Med. 2020;59(2):433–440. DOI:10.1515/cclm-2020-1361
   PubMed Web of Science ®Google Scholar
• Heer RS, Mandal AKJ, Kho J, et al. Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection. Ann Clin Biochem. 2021;58(5):520–527. DOI:10.1177/00045632211022380
   PubMed Web of Science ®Google Scholar
• Atallah NJ, Warren HM, Roberts MB, et al. Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: a case-control study. PLoS ONE. 2022;17(1):e0262342. DOI:10.1371/journal.pone.0262342
   PubMed Web of Science ®Google Scholar
• Kooistra EJ, van Berkel M, van Kempen NF, et al. Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients. Crit Care. 5 aug 2021;25(1):281.
   Google Scholar
• Moreno-García E, Puerta-Alcalde P, Letona L, et al. Bacterial co-infection at hospital admission inpatients with COVID-19. IntJ Infect Dis. 2022;118:197‑202. mai.
   PubMed Web of Science ®Google Scholar
• Williams EJ, Mair L, de Silva TL, et al. Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study. J Hosp Infect. 2021;110:103–107.
   PubMed Web of Science ®Google Scholar
• Minnaard MC, de Groot JAH, Hopstaken RM, et al. The added value of C-reactive protein measurement in diagnosing pneumonia in primary care: a meta-analysis of individual patient data. CMAJ : Can Med Assoc J = Journal de L’association Medicale Canadienne. 2017;189(2):E56–63. DOI:10.1503/cmaj.151163
   PubMed Web of Science ®Google Scholar
• Boere TM, van Buul LW, Hopstaken RM, et al. Effect of C reactive protein point-of-care testing on antibiotic prescribing for lower respiratory tract infections in nursing home residents: cluster randomised controlled trial. BMJ. 2021;374:n2198.
   PubMedGoogle Scholar
• Copaescu A, James F, Mouhtouris E, et al. The role of immunological and clinical biomarkers to predict clinical COVID-19 severity and response to therapy—a prospective longitudinal study. Front Immunol. 2021;12:758.
   Web of Science ®Google Scholar
• Mason CY, Kanitkar T, Richardson CJ, et al. Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. J Antimicrob Chemother. 2021;76(5):1323–1331. DOI:10.1093/jac/dkaa563
   PubMed Web of Science ®Google Scholar
• Li HK, Kaforou M, Rodriguez-Manzano J, et al. Discovery and validation of a three-gene signature to distinguish COVID-19 and other viral infections in emergency infectious disease presentations: a case-control and observational cohort study. Lancet Microbe. 2021;2(11):e594–603. DOI:10.1016/S2666-5247(21)00145-2
   PubMedGoogle Scholar
• Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell. 2021;184(7):1671–1692.
   PubMed Web of Science ®Google Scholar
• Zahariadis G, Gooley TA, Ryall P, et al. Risk of ruling out severe acute respiratory syndrome by ruling in another diagnosis: variable incidence of atypical bacteria coinfection based on diagnostic assays. Can Respir J. 2006;13(1):17–22. DOI:10.1155/2006/862797
   PubMedGoogle Scholar
• Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of middle east respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752–761. DOI:10.1016/S1473-3099(13)70204-4
   PubMed Web of Science ®Google Scholar
• Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266–275.
   PubMed Web of Science ®Google Scholar
• Musuuza JS, Watson L, Parmasad V, et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS ONE. 2021;16(5):e0251170. DOI:10.1371/journal.pone.0251170
   PubMed Web of Science ®Google Scholar
• Soriano MC, Vaquero C, Ortiz-Fernández A, et al. Low incidence of co-infection, but high incidence of ICU-acquired infections in critically ill patients with COVID-19. J Infect. 2021;82(2):e20. DOI:10.1016/j.jinf.2020.09.010
   PubMed Web of Science ®Google Scholar
• Fumagalli J, Panigada M, Klompas M, et al. Ventilator-associated pneumonia among SARS-CoV-2 acute respiratory distress syndrome patients. Curr Opin Crit Care. 2022;28(1):74.
   PubMed Web of Science ®Google Scholar
• Bardi T, Pintado V, Gomez-Rojo M, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur j Clin Microbiol infect dis : off publ Eur Soc Clin Microbiol. 2021;40(3):495–502. DOI:10.1007/s10096-020-04142-w
   PubMed Web of Science ®Google Scholar
• Falcone M, Tiseo G, Giordano C, et al. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. J Antimicrob Chemother. 2021;76(4):1078–1084. DOI:10.1093/jac/dkaa530
   PubMed Web of Science ®Google Scholar
• Gamberini L, Tonetti T, Spadaro S, et al. Factors influencing liberation from mechanical ventilation in coronavirus disease 2019: multicenter observational study in fifteen Italian ICUs. J Intensive Care. 2020;8(1): DOI:10.1186/s40560-020-00514-8
   Web of Science ®Google Scholar
• Gayam V, Konala VM, Naramala S, et al. Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and Mycoplasma pneumoniae in the USA. J med virol. 2020;92(10):2181–2187. DOI:10.1002/jmv.26026
   PubMed Web of Science ®Google Scholar
• Arashiro T, Nakamura S, Asami T, et al. SARS-CoV-2 and Legionella co-infection in a person returning from a Nile cruise. J Travel Med. 2020;27(3):1–3. DOI:10.1093/jtm/taaa053
   Web of Science ®Google Scholar
• Oliva A, Siccardi G, Migliarini A, et al. Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature. Infection. 2020;48(6):871–877. DOI:10.1007/s15010-020-01483-8
   PubMed Web of Science ®Google Scholar
• Chaudhry R, Sreenath K, Batra P, et al. Atypical bacterial co-infections among patients with COVID-19: a study from India. J Med Virol. 2022 Jan;94(1):303–309. DOI:10.1002/jmv.27324.
   PubMed Web of Science ®Google Scholar
• de Francesco MA, Poiesi C, Gargiulo F, et al. Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. J Infect. 2021;82(4):e4. DOI:10.1016/j.jinf.2021.01.009
   PubMed Web of Science ®Google Scholar
• Meyer Sauteur PM, Beeton ML, Uldum SA, et al. Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021. Euro Surveill. 2022 May;27(19):2100746. DOI:10.2807/1560-7917.ES.2022.27.19.2100746.
   PubMedGoogle Scholar
• Verhasselt HL, Buer J, Dedy J, et al. COVID-19 co-infection with legionella pneumophila in 2 tertiary-care hospitals, Germany. Emerg Infect Dis. 2021;27(5):1535–1537. DOI:10.3201/eid2705.203388
   PubMed Web of Science ®Google Scholar
• Rothe K, Feihl S, Schneider J, et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur j Clin Microbiol infect dis : off publ Eur Soc Clin Microbiol. 2021;40(4):859–869. DOI:10.1007/s10096-020-04063-8
   PubMed Web of Science ®Google Scholar
• Cohen R, Finn T, Babushkin F, et al. High rate of bacterial respiratory tract co-infections upon admission amongst moderate to severe COVID-19 patients. Infect Dis (Auckl). 2022;54(2):134–144. DOI:10.1080/23744235.2021.1985732
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27(1):83–88. DOI:10.1016/j.cmi.2020.07.041
   PubMed Web of Science ®Google Scholar
• Mendelson M. Could enhanced influenza and pneumococcal vaccination programs help limit the potential damage from SARS-CoV-2 to fragile health systems of southern hemisphere countries this winter? Int J Infect Dis. 2020;94:32–33.
   PubMed Web of Science ®Google Scholar
• Desai A, Santonocito OG, Caltagirone G, et al. Effectiveness of streptococcus pneumoniae urinary antigen testing in decreasing mortality of COVID-19 co-infected patients: a clinical investigation. Medicina (Kaunas). 2020;56(11):1–10. DOI:10.3390/medicina56110572
   Web of Science ®Google Scholar
• Thelen JM, Buenen AG (Noud), van Apeldoorn M , et al. Community-acquired bacteraemia in COVID-19 in comparison to influenza a and influenza B: a retrospective cohort study. BMC Infect Dis. 2021;21(1): (Noud). doi:10.1186/s12879-021-05902-5.
   PubMed Web of Science ®Google Scholar
• Mormeneo Bayo S, Palacián Ruíz MP, Moreno Hijazo M, et al. Bacteremia during COVID-19 pandemic in a tertiary hospital in Spain. Enferm Infecc Microbiol Clin. 2021;40(4):183–186. DOI:10.1016/j.eimce.2021.01.007
   Web of Science ®Google Scholar
• Hughes S, Troise O, Donaldson H, et al. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26(10):1395–1399. DOI:10.1016/j.cmi.2020.06.025
   PubMed Web of Science ®Google Scholar
• Lardaro T, Wang AZ, Bucca A, et al. Characteristics of COVID-19 patients with bacterial coinfection admitted to the hospital from the emergency department in a large regional healthcare system. J med virol. 2021;93(5):2883–2889. DOI:10.1002/jmv.26795
   PubMed Web of Science ®Google Scholar
• Sepulveda J, Westblade LF, Whittier S, et al. Bacteremia and blood culture utilization during COVID-19 surge in New York City. J Clin Microbiol. 2020;58(8): DOI:10.1128/JCM.00875-20
   Web of Science ®Google Scholar
• Giacobbe DR, Battaglini D, Ball L, et al. Bloodstream infections in critically ill patients with COVID-19. Eur J Clin Invest. 2020 Oct;50(10):e13319. DOI:10.1111/eci.13319.
   PubMed Web of Science ®Google Scholar
• Buetti N, Ruckly S, de Montmollin E, et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network. Intensive care Med. 2021 Feb;47(2):180–187. DOI:10.1007/s00134-021-06346-w.
   PubMed Web of Science ®Google Scholar
• Townsend L, Hughes G, Kerr C, et al. Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection. JAC-antimicrobial resistance. 2020;2(3): DOI:10.1093/jacamr/dlaa071
   Google Scholar
• Karataş M, Yaşar-Duman M, Tünger A, et al. Secondary bacterial infections and antimicrobial resistance in COVID-19: comparative evaluation of pre-pandemic and pandemic-era, a retrospective single center study. Ann Clin Microbiol Antimicrob. 2021;20(1):51. DOI:10.1186/s12941-021-00454-7
   PubMed Web of Science ®Google Scholar
• Yang S, Hua M, Liu X, et al. Bacterial and fungal co-infections among COVID-19 patients in intensive care unit. Microbes Infect. 2021;23(4–5):104806. DOI:10.1016/j.micinf.2021.104806
   PubMed Web of Science ®Google Scholar
• Buetti N, Mazzuchelli T, Lo Priore E, et al. Early administered antibiotics do not impact mortality in critically ill patients with COVID-19. J Infect. 2020;81(2):e148. DOI:10.1016/j.jinf.2020.06.004
   PubMed Web of Science ®Google Scholar
• Singh V, Upadhyay P, Reddy J, et al. SARS-CoV-2 respiratory co-infections: incidence of viral and bacterial co-pathogens. Inter J Infect Dis. 2021;105:617–620.
   PubMed Web of Science ®Google Scholar
• Soto A, Quiñones-Laveriano DM, Valdivia F, et al. Detection of viral and bacterial respiratory pathogens identified by molecular methods in COVID-19 hospitalized patients and its impact on mortality and unfavorable outcomes. Infect Drug Resist. 2021;14:2795.
   PubMed Web of Science ®Google Scholar
• Van Laethem J, Wuyts S, van Laere S, et al. Antibiotic prescriptions in the context of suspected bacterial respiratory tract superinfections in the COVID-19 era: a retrospective quantitative analysis of antibiotic consumption and identification of antibiotic prescription drivers. Int Emerg Med. 2022;17(1):141–151. DOI:10.1007/s11739-021-02790-0
   PubMed Web of Science ®Google Scholar
• Seaton RA, Gibbons CL, Cooper L, et al. Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. J Infect. 2020;81(6):952–960. DOI:10.1016/j.jinf.2020.09.024
   PubMed Web of Science ®Google Scholar
• Van Laethem J, Wuyts S, van Laere S, et al. Antibiotic prescriptions targeting bacterial respiratory infections in admitted patients with COVID-19: a Prospective Observational Study. Infect Dis Ther. 2021;10(4):2575–2591. DOI:10.1007/s40121-021-00535-2
   PubMed Web of Science ®Google Scholar
• Cataño-Correa JC, Cardona-Arias JA, Mancilla JPP, et al. Bacterial superinfection in adults with COVID-19 hospitalized in two clinics in Medellín-Colombia, 2020. PLoS ONE. 2021;16(7):e0254671. DOI:10.1371/journal.pone.0254671
   PubMed Web of Science ®Google Scholar
• Vaughn VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clin Infect Dis. 2021;72(10):e533. DOI:10.1093/cid/ciaa1239
   PubMed Web of Science ®Google Scholar
• Grasselli G, Scaravilli V, Mangioni D, et al. Hospital-Acquired Infections in Critically Ill Patients with COVID-19. Chest. 2021;160(2):454–465. DOI:10.1016/j.chest.2021.04.002
   PubMed Web of Science ®Google Scholar
• Derde LPG, Gordon AC, Mouncey PR, et al. Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial. medRxiv 2021: 2021.06.18.21259133.
   Google Scholar
• Mariette X, Hermine O, Resche-Rigon M, et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021;9(3):295–304. DOI:10.1016/S2213-2600(20)30556-7
   PubMed Web of Science ®Google Scholar
• Declercq J, van Damme KFA, de Leeuw E, et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respir Med. 2021;9(12):1427–1438. DOI:10.1016/S2213-2600(21)00377-5
   PubMed Web of Science ®Google Scholar
• World Health Organization. Therapeutics and COVID-19: living guideline. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.2.
   Google Scholar
• ICH. ICH harmonized tripartite guideline: guideline for good clinical practice. J Postgrad Med. 2001;47:45.
   PubMedGoogle Scholar
• Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407–1418. DOI:10.1016/S2213-2600(21)00331-3
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807. DOI:10.1056/NEJMoa2031994
   PubMed Web of Science ®Google Scholar
• Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022 9 (12) ;1407–1418.
   Google Scholar
• Jeronimo CMP, Farias MEL, Val FFA, et al. methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase iib, placebo-controlled trial. Clin Infect Dis. 2021;72(9):e373–81. DOI:10.1093/cid/ciaa1177
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704.
   PubMed Web of Science ®Google Scholar
• Milas S, Poncelet A, Buttafuoco F, et al. Antibiotic use in patients with Coronavirus disease 2019 (COVID-19): outcomes and associated factors. Acta Clin Belg. 2021;77(3):579–587. DOI:10.1080/17843286.2021.1916300
   PubMed Web of Science ®Google Scholar
• Maincent C, Perrin C, Chironi G, et al. Microvascular injuries, secondary edema, and inconsistencies in lung vascularization between affected and nonaffected pulmonary segments of non-critically ill hospitalized COVID-19 patients presenting with clinical deterioration. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221096040. DOI:10.1177/17534666221096040.
   Web of Science ®Google Scholar
• Kang M, Hong KS, Chikontwe P, et al. Quantitative assessment of chest CT Patterns in COVID-19 and bacterial pneumonia patients: a deep learning perspective. J Korean Med Sci. 2021;36(5): DOI:10.3346/jkms.2021.36.e46
   Web of Science ®Google Scholar
• Zheng F, Li L, Zhang X, et al. Accurately discriminating COVID-19 from viral and bacterial pneumonia according to CT images via deep learning. Interdiscip Sci. 2021;13(2):273–285. DOI:10.1007/s12539-021-00420-z
   PubMed Web of Science ®Google Scholar
• Wang S, Zha Y, Li W, et al. A fully automatic deep learning system for COVID-19 diagnostic and prognostic analysis. Eur Respir J. 2020;56(2):2000775. DOI:10.1183/13993003.00775-2020
   PubMed Web of Science ®Google Scholar